Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
02:01pm, Tuesday, 14'th May 2024
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript
07:31pm, Monday, 13'th May 2024
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affairs & Brand Strategy Officer David Cha
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
06:11pm, Monday, 13'th May 2024
Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.38 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago.
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
04:47pm, Monday, 13'th May 2024
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
04:01pm, Monday, 13'th May 2024
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
08:30am, Monday, 06'th May 2024
SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
SOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 24'th Apr 2024
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investing in the technologies of tomorrow can be a lucrative investment strategy. If investors can discern trends as they develop, they can stay ahead of the curve and reap the rewards.
3 Meme Stocks to Sell and Replace With Meme Coins
02:45pm, Thursday, 11'th Apr 2024
Social media has largely overshadowed the investing fundamentals with pumpamentals, spotlighting meme stocks to sell. Just as Bitcoin is analog to blue-chip stocks, meme stocks have similarly become a
Allogene Therapeutics Announces Q2 Investor Conference Participation
08:30am, Tuesday, 09'th Apr 2024
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
How Allogene (ALLO) Stock Stands Out in a Strong Industry
09:50am, Monday, 08'th Apr 2024
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
10:36am, Friday, 15'th Mar 2024
Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.
Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript
08:49pm, Thursday, 14'th Mar 2024
Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
06:16pm, Thursday, 14'th Mar 2024
Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.66 per share a year ago.
